Roche to present latest cancer care data at ESMO 2025

Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant

AstraZeneca to unveil breakthrough cancer trial results at ESMO 2025

The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types

Lupin to present Phase 1 Data on STING agonist at the ESMO Congress 2025

The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors

Novo Nordisk to acquire Akero Therapeutics for $5.2 billion

Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases

Merck advances cancer innovation by expanding role of Keytruda across new tumor

The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025

AstraZeneca to increase investment in Virginia manufacturing facility to $4.5 billion

Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America

VectorBuilder Redefines Plasmid Standards with miniVec

Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively

AstraZeneca Pharma India receives sale, distribution approval from CDSCO for Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder

Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors

FDA grants De Novo classification to first needle-free, glucose sensor Biolinq Shine

Biocon Biologics secures US market entry date for Bosaya and Aukelso, Denosumab biosimilars